At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Trading 07-20 14:11:08 EDT
26.96
-0.13
-0.48%
High27.17Low26.46Vol179.20K
Open27.15D1 Closing27.09Amplitude2.63%
Mkt Cap2.38BTradable Cap1.78BTotal Shares88.16M
T/O4.80MT/O Rate0.27%Tradable Shares66.03M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 559,234 in Common Shares
Reuters  ·  07-16
Mineralys Therapeutics CMO David Malcom Rodman Disposes of USD 559,234 in Common Shares
Mineralys CMO David Malcom Rodman Sells 2,171 Common Shares Worth $65,781.30
Reuters  ·  07-11
Mineralys CMO David Malcom Rodman Sells 2,171 Common Shares Worth $65,781.30
Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?
Simply Wall St.  ·  07-06
Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative?
Have Insiders Sold Mineralys Therapeutics Shares Recently?
Simply Wall St.  ·  07-03
Have Insiders Sold Mineralys Therapeutics Shares Recently?
Mineralys Therapeutics (MLYS) Left Key Russell Indexes, Is The Stock Still Below Fair Value?
Simply Wall St.  ·  07-02
Mineralys Therapeutics (MLYS) Left Key Russell Indexes, Is The Stock Still Below Fair Value?
Mineralys CCO Eric Warren Disposes of 104,124 Common Shares for $2.7 Million
Reuters  ·  07-01
Mineralys CCO Eric Warren Disposes of 104,124 Common Shares for $2.7 Million
Mineralys Therapeutics director Daphne Karydas sells 3,000 shares valued at $75,000
Reuters  ·  06-18
Mineralys Therapeutics director Daphne Karydas sells 3,000 shares valued at $75,000
Mineralys posts ENDO 2026 lorundrostat biomarker presentation on uncontrolled hypertension
Reuters  ·  06-15
Mineralys posts ENDO 2026 lorundrostat biomarker presentation on uncontrolled hypertension
Mineralys Therapeutics presents late-breaking data on lorundrostat
TIPRANKS  ·  06-15
Mineralys Therapeutics presents late-breaking data on lorundrostat
Mineralys says lorundrostat reduces heart failure risk biomarkers in post hoc analysis of hypertension trials
Reuters  ·  06-14
Mineralys says lorundrostat reduces heart failure risk biomarkers in post hoc analysis of hypertension trials
Mineralys CMO David Malcom Rodman disposes of common shares worth $203,512.74
Reuters  ·  06-13
Mineralys CMO David Malcom Rodman disposes of common shares worth $203,512.74
Mineralys Therapeutics to join Goldman Sachs Global Healthcare Conference fireside chat
Reuters  ·  06-09
Mineralys Therapeutics to join Goldman Sachs Global Healthcare Conference fireside chat
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
GlobeNewswire  ·  06-09
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)
TIPRANKS  ·  06-04
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)
Mineralys Therapeutics falls -12.7%
TIPRANKS  ·  06-03
Mineralys Therapeutics falls -12.7%
Mineralys prices offering of 5.66M shares of common stock at $26.50
TIPRANKS  ·  06-03
Mineralys prices offering of 5.66M shares of common stock at $26.50
BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
Reuters  ·  06-03
BUZZ-U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
BUZZ-Mineralys Therapeutics falls after $150 mln stock deal
Reuters  ·  06-03
BUZZ-Mineralys Therapeutics falls after $150 mln stock deal
BRIEF-Mineralys Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock
Reuters  ·  06-03
BRIEF-Mineralys Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock
Mineralys to repurchase future royalty payments in Tanabe license agreement
TIPRANKS  ·  06-03
Mineralys to repurchase future royalty payments in Tanabe license agreement

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--